The United Kingdom and the United States have secured a landmark commercial pact that will maintain no duties on British drug products going into the US market.
Key Provisions of the Accord
Under the terms of the agreement, the UK has committed to raise expenditure on pharmaceuticals through the National Health Service (NHS). This pledge secures that duties on these vital products will remain at zero for a timeframe of three years.
This deal is in response to earlier statements to significantly raise tariffs on patented pharmaceutical products, with figures floated reaching 100%.
"This deal between the United Kingdom reinforces the worldwide climate for innovative medicines and brings long-overdue fairness to transatlantic medicine commerce," an announcement declared.
Commercial Importance
Drugs represent one of the the United Kingdom's most significant goods shipped to the United States, which is easily the biggest market for leading UK drugmakers.
Statistics show that in the 12 months leading up to the third quarter, the UK shipped drugs totaling £11.1bn to the US. This value accounted for nearly one-fifth of total UK exports in that period.
"This agreement protects employment, stimulates capital expenditure and facilitates the UK to establish itself as a international leader for life sciences," a government official stated.
Key UK Commitments
The agreement involves several specific commitments from the UK:
- Price Threshold Increase: The UK will raise the affordability limit at which it deems new therapies to be prohibitively costly by 25%.
- Increased NHS Spending: There is a target to increase overall NHS spending on medicines from 0.3% of Gross Domestic Product to 0.6% over the coming ten years.
- Payback Limit: The amount drug companies must refund to the NHS to stay within budget will be limited at 15%. Last year, refunds were more than twenty percent.
Recent Tensions
The deal follows a ongoing dispute between the drug companies and the UK government over drug pricing and regulatory access.
This friction were heightened by claims that US customers were paying significantly more for the same drugs than people in the Britain and the EU.
Over the last 18 months, several large drug company projects in the UK have been delayed or scrapped, while substantial investments have been pledged toward American operations.
One official acknowledged that the NHS needed to invest a greater share on medicines, noting that its budget allocation on drugs had decreased as a percentage of its resources over the past decade.
